pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ABBVIE · news · pharmadog
← back to ABBVIE
News mentioning ABBVIE
229
stories
Oct 19, 26
Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep
biospace
Oct 19, 26
Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweep
biospace
Oct 19, 26
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
fiercebiotech
Oct 19, 26
ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space
fiercebiotech
Oct 16, 26
Iambic CEO on taking an AI drug company public
biopharma dive
Oct 15, 26
Chutes & Ladders—Bausch + Lomb's returning CEO Saunders exits again
fiercebiotech
Oct 15, 26
Belgian startup revives Galapagos CAR-T research
biopharma dive
Oct 15, 26
Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
fiercebiotech
Oct 15, 26
Iambic, an AI drug discovery specialist, banks $150M in an IPO
biopharma dive
Oct 13, 26
Another Paragon spinout goes public through reverse merger
biopharma dive
Oct 13, 26
Apogee execs join Paragon to scale its R&D, company creation engine
endpoints
Oct 13, 26
Biotech builder Paragon imports Apogee's top brass after AbbVie buyout
fiercebiotech
Oct 13, 26
Nurix drops one BTK degrader as momentum builds behind Roche-partnered option
fiercebiotech
Oct 12, 26
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
Oct 9, 26
‘We’re making a lot of progress’: How Nobel-winning optogenetics is being harnessed by biotechs
fiercebiotech
Oct 8, 26
AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic
fiercebiotech
Oct 7, 26
Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDA
biospace
Oct 7, 26
Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up
biospace
Oct 7, 26
Cerevance rescues its Parkinson's drug with phase 3 win
fiercebiotech
Oct 7, 26
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
biospace
Oct 6, 26
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
biopharma dive
Oct 6, 26
AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3
biospace
Oct 6, 26
AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
endpoints
Oct 5, 26
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
biospace
Oct 5, 26
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
fiercebiotech
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Oct 2, 26
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
biospace
Oct 1, 26
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
Oct 1, 26
3 takeaways from a European obesity scientific meeting
biopharma dive
Oct 1, 26
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
← prev
page 3 of 8
next →